QURE
Price
$15.38
Change
+$1.13 (+7.93%)
Updated
Jul 23, 04:59 PM (EDT)
Capitalization
780.17M
8 days until earnings call
TRVI
Price
$8.00
Change
+$0.99 (+14.14%)
Updated
Jul 23, 04:44 PM (EDT)
Capitalization
852.28M
15 days until earnings call
Interact to see
Advertisement

QURE vs TRVI

Header iconQURE vs TRVI Comparison
Open Charts QURE vs TRVIBanner chart's image
uniQure
Price$15.38
Change+$1.13 (+7.93%)
Volume$33.77K
Capitalization780.17M
Trevi Therapeutics
Price$8.00
Change+$0.99 (+14.14%)
Volume$5.09K
Capitalization852.28M
QURE vs TRVI Comparison Chart in %
Loading...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
QURE vs. TRVI commentary
Jul 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is QURE is a StrongBuy and TRVI is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 23, 2025
Stock price -- (QURE: $14.50 vs. TRVI: $6.82)
Brand notoriety: QURE and TRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: QURE: 70% vs. TRVI: 57%
Market capitalization -- QURE: $780.17M vs. TRVI: $852.28M
QURE [@Biotechnology] is valued at $780.17M. TRVI’s [@Biotechnology] market capitalization is $852.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $284.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

QURE’s FA Score shows that 0 FA rating(s) are green whileTRVI’s FA Score has 0 green FA rating(s).

  • QURE’s FA Score: 0 green, 5 red.
  • TRVI’s FA Score: 0 green, 5 red.
According to our system of comparison, TRVI is a better buy in the long-term than QURE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

QURE’s TA Score shows that 3 TA indicator(s) are bullish while TRVI’s TA Score has 5 bullish TA indicator(s).

  • QURE’s TA Score: 3 bullish, 6 bearish.
  • TRVI’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, TRVI is a better buy in the short-term than QURE.

Price Growth

QURE (@Biotechnology) experienced а -0.34% price change this week, while TRVI (@Biotechnology) price change was -2.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.08%. For the same industry, the average monthly price growth was +21.29%, and the average quarterly price growth was +31.06%.

Reported Earning Dates

QURE is expected to report earnings on Oct 29, 2025.

TRVI is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+7.08% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TRVI($852M) has a higher market cap than QURE($780M). TRVI YTD gains are higher at: 65.534 vs. QURE (-17.894). TRVI has higher annual earnings (EBITDA): -47.23M vs. QURE (-138.01M). QURE has more cash in the bank: 409M vs. TRVI (103M). TRVI has less debt than QURE: TRVI (957K) vs QURE (66.2M). QURE has higher revenues than TRVI: QURE (20.2M) vs TRVI (0).
QURETRVIQURE / TRVI
Capitalization780M852M92%
EBITDA-138.01M-47.23M292%
Gain YTD-17.89465.534-27%
P/E RatioN/AN/A-
Revenue20.2M0-
Total Cash409M103M397%
Total Debt66.2M957K6,917%
FUNDAMENTALS RATINGS
QURE vs TRVI: Fundamental Ratings
QURE
TRVI
OUTLOOK RATING
1..100
69
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
59
Fair valued
PROFIT vs RISK RATING
1..100
10080
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
4737
P/E GROWTH RATING
1..100
91100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRVI's Valuation (59) in the Pharmaceuticals Major industry is in the same range as QURE (78) in the Biotechnology industry. This means that TRVI’s stock grew similarly to QURE’s over the last 12 months.

TRVI's Profit vs Risk Rating (80) in the Pharmaceuticals Major industry is in the same range as QURE (100) in the Biotechnology industry. This means that TRVI’s stock grew similarly to QURE’s over the last 12 months.

TRVI's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as QURE (100) in the Biotechnology industry. This means that TRVI’s stock grew similarly to QURE’s over the last 12 months.

TRVI's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as QURE (47) in the Biotechnology industry. This means that TRVI’s stock grew similarly to QURE’s over the last 12 months.

QURE's P/E Growth Rating (91) in the Biotechnology industry is in the same range as TRVI (100) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to TRVI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
QURETRVI
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 7 days ago
74%
Bullish Trend 6 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FNIDX14.220.07
+0.49%
Fidelity Intl Sustainability Idx
NMMEX17.220.08
+0.47%
Northern Active M Emerging Market Equity
NSGCX19.610.03
+0.15%
Columbia Select Large Cap Equity C
LAFVX19.99-0.06
-0.30%
Lord Abbett Affiliated R6
SPMCX7.85-0.08
-1.01%
Saratoga Mid Capitalization C

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with PTGX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
-0.58%
PTGX - TRVI
43%
Loosely correlated
-0.47%
BIESF - TRVI
43%
Loosely correlated
N/A
GOSS - TRVI
34%
Loosely correlated
+2.94%
MLYS - TRVI
32%
Poorly correlated
-4.29%
QURE - TRVI
30%
Poorly correlated
-3.27%
More